Randomized Comparison of Oral Valacyclovir and Intravenous Ganciclovir for Prevention of Cytomegalovirus Disease after Allogeneic Bone Marrow Transplantation

Winston, Drew J.; Yeager, Andrew M.; Chandrasekar, Pranatharthi H.; Snydman, David R.; Petersen, Finn Bo; Territo, Mary C.
March 2003
Clinical Infectious Diseases;3/15/2003, Vol. 36 Issue 6, p749
Academic Journal
In this multicenter, randomized study, cytomegalovirus (CMV)-seropositive patients who received an allogeneic bone marrow transplant were provided high-dose intravenous acyclovir (500 mg/m[SUP2] q8h) from the day of transplantation until engraftment. The patients were then randomly assigned to receive either oral valacyclovir, 2 g q.i.d. (n = 83), or intravenous ganciclovir, 5 mg/kg q12h for 1 week, then 6 mg/kg once daily for 5 days per week (n = 85), until day 100 after transplantation. CMV infection occurred in 12% of the patients who received valacyclovir and in 19% of the patients who received ganciclovir (hazard ratio [HR], 1.042; 95% confidence interval [CI], 0.391-2.778; P = .934). CMV disease developed in only 2 patients who received valacyclovir and in 1 patient who received ganciclovir (HR, 1.943; 95% CI, 0.176-21.44; P = .588). Oral valacyclovir can be an effective alternative to intravenous ganciclovir for prophylaxis of CMV disease after bone marrow transplantation.


Related Articles

  • Activity of 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia. Shepp, David H.; Dandliker, Paula S.; Miranda, Paulo de; Burnette, Thimysta C.; Cederberg, Donna M.; Kirk, L. Edward; Myers, Joel D.; Shepp, D H; Dandliker, P S; de Miranda, P; Burnette, T C; Cederberg, D M; Kirk, L E; Meyers, J D // Annals of Internal Medicine;Sep85, Vol. 103 Issue 3, p368 

    Ten marrow transplant recipients with biopsy-proven cytomegalovirus pneumonia were treated with the acyclic nucleoside analog 9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl]guanine (BW B759U). Viruria and viremia ceased after 4 days of treatment in all patients with cultures initially positive from...

  • Late Cytomegalovirus Pneumonia in Adult Allogeneic Blood and Marrow Transplant Recipients. Nguyen, Q.; Champlin, R.; Rolston, K.; Raad, I.; Jacobson, K.; Ippoliti, C.; Hecht, D.; Tarrand, J.; Luna, M.; Whimbey, E.; Giralt, S. // Clinical Infectious Diseases;3/1/1999, Vol. 28 Issue 3, p618 

    Assesses the impact of antiviral prophylaxis months after transplantation on the frequency, timing, and outcome of cytomegalovirus (CMV) pneumonia during the first year in adult allogenic blood and marrow transplant recipients. Late occurrence of episodes; Association of late CMV pneumonia with...

  • Cytomegalovirus-Associated Tubulointerstitial Nephritis in an Allogeneic Bone Marrow Transplant Recipient. Shorr, Ronald I.; Longgo, Walter L.; Oberley, Terry D.; Bozdech, Marek J.; Walker, Duard L. // Annals of Internal Medicine;Sep87, Vol. 107 Issue 3, p351 

    Presents a medical case involving a patient with cytomegalovirus-associated tubulointerstitial nephritis in an allogeneic bone marrow transplant recipient. Information on hematuria; Profile of the patient; Treatment administered; Results of the treatment.

  • Cell Medica Raises £1.95M to Expand Cell Therapy Work. Moran, Nuala // BioWorld International;9/23/2009, Vol. 14 Issue 38, p2 

    The article reports that Cell Medica Ltd. raised 1.95 million British pounds from existing shareholders to develop further applications for its cell therapy technique for protecting patients with weakened immune systems against cytomegalovirus (CMV) infections. Cell Medica's Virus-specific...

  • Ganciclovir: An Update of its Use in the Prevention of Cytomegalovirus Infection and Disease in Transplant Recipients. McGavin, J.K.; Goa, K.L. // Drugs;Jun2001, Vol. 61 Issue 8, p1153 

    Ganciclovir is a nucleoside guanosine analogue which incorporates ganciclovir triphosphate (the active moiety) into DNA during elongation, thereby inhibiting viral replication. Comparative studies of pre-emptive and prophylactic ganciclovir therapies in bone marrow transplant (BMT) recipients...

  • Recombinant TLR5 Agonist CBLB502 Promotes NK Cell-Mediated Anti-CMV Immunity in Mice. Hossain, Mohammad S.; Ramachandiran, Sampath; Gewirtz, Andrew T.; Waller, Edmund K. // PLoS ONE;May2014, Vol. 9 Issue 5, p1 

    Prior work using allogeneic bone marrow transplantation (allo-BMT) models showed that peritransplant administration of flagellin, a toll-like receptor 5 (TLR5) agonist protected murine allo-BMT recipients from CMV infection while limiting graft-vs-host disease (GvHD). However, the mechanism by...

  • Visual compatibility of i.v. medications routinely used in bone marrow transplant recipients. Canann, David; Tyler, Linda S.; Barker, Brian; Condie, Chad // American Journal of Health-System Pharmacy;4/15/2009, Vol. 66 Issue 8, p727 

    Purpose. The visual compatibility of i.v. medications routinely used in bone marrow transplant recipients was studied. Methods. A total of 17 drug combinations were tested using simulated Y-site administration. Medications were prepared to the standard concentrations used at University of Utah...

  • news briefs.  // Dermatology Times;Sep2010, Vol. 31 Issue 9, p18 

    The article offers medicine-related news briefs. The U.S. Food and Drug Administration (FDA) has given its approval for Xeomin to treat blepharospasm and cervical dystonia in adults. The study conducted by the researchers at the University of Minnesota, Minneapolis reveals that bone marrow...

  • Transfusions and gay men: One case. REHWINKEL, CHASSE // Windy City Times;8/19/2009, Vol. 24 Issue 46, p6 

    The article focuses on issues related to the U.S. Food and Drug Administration's policy which prohibits sexually active gay males from donating their bone marrow.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics